Enlivex Therapeutics Ltd (ENLV) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Enlivex Therapeutics Ltd  (NASDAQ: ENLV)


Enlivex Therapeutics Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Enlivex Therapeutics Ltd's ROA in the fourth quarter of 2025?
Enlivex Therapeutics Ltd achieved a return on average assets (ROA) of 52.72 % in its fourth quarter of 2025, this is above ENLV's average return on assets of -45.67%.
Enlivex Therapeutics Ltds assets during the 12 months ending in the fourth quarter of 2025 are valued at $2 billion

ROA has improved compared to -0.48% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 22 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 88.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Total Assets Change 6570.81 % 7321.93 % 3057.49 % 6218.04 % -34.59 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 1,230 -8 -13 -40 -36
Return On Assets (TTM) 52.72 % -0.48 % -1.06 % -6.44 % -81.84 %
ENLV's Total Ranking # 88 # # # # 4866
Total Assets (TTM) in million 2,335 2,327 2,344 2,327 35
Seq. Total Assets Change 0.33 % -0.74 % 0.75 % 6548.95 % 11.63 %
Seq. Net Income Change - - - - -

ENLV's 5 Years Annual ROA >> Back to ENLV Management Effectiveness >> Compare ENLV ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 7
Sector # 23
Overall # 85

Return On Assets Statistics
High Average Low
74.89 %
-45.67 %
-164.14 %
(Dec 31 2015)   (Dec 31 2017)





Financial Statements
Enlivex Therapeutics Ltd's Assets $ 2,335 million ENLV's Balance sheet
Enlivex Therapeutics Ltd's Income $ 1,236 million Quarterly ENLV's Income Statement
ENLV's Income by Division See ENLV's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 6570.81 % -52.86 % -21.4 % -27.98 % 166.98 %
Total Assets in million 2,335 35 74 94 131
Y / Y Net Income Change - - - - -
Net Income in million 1,236 -15 -29 -31 -14
Annual Return On Assets 52.92 % -42.9 % -39.15 % -32.88 % -11.03 %

ENLV's 5 Years Annual ROA >> Back to ENLV Management Effectiveness >> Compare ENLV ROA to its Competitors



Comment on ENLV's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 52.92 % compared to prior year, due to annual net income growth of % to $1,235.53 million, while value of Enlivex Therapeutics Ltd's overall assets grew just by 6570.81 % to $2,334.65 million, compared to $2,334.65 a year before.


More Return On Assets Ratios
ENLV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ENLV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ENLV's Competitors
Subscribers only: Roa for Enlivex Therapeutics Ltd's Suppliers
Subscribers only: Return On Assets for ENLV's Customers

You may also want to know
ENLV's Roi ENLV's Inventory Turnover Ratio ENLV's Growth Rates ENLV's Dividend Comparisons
ENLV's Profitability Ratios ENLV's Asset Turnover Ratio ENLV's Dividend Growth
ENLV's Roe ENLV's Valuation Ratios ENLV's Financial Strength Ratios ENLV's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Silexion Therapeutics Corp  144.68 %
Interpace Biosciences Inc   135.21 %
Elutia Inc   129.48 %
Rigel Pharmaceuticals Inc  128.91 %
Capforce Inc   127.99 %
Kyntra Bio Inc   122.33 %
Icecure Medical Ltd  108.42 %
Atara Biotherapeutics Inc   87.55 %
Traws Pharma inc   86.12 %
Sanuwave Health Inc   65.98 %
Exelixis Inc   61.66 %
Entera Bio Ltd   61.28 %
Biocryst Pharmaceuticals Inc   55.61 %
Check Cap Ltd  55.30 %
Advanced Biomed Inc.  53.63 %
Enlivex Therapeutics Ltd  53.10 %
Tg Therapeutics Inc   51.88 %
Aurinia Pharmaceuticals Inc   50.24 %
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %

Date modified: 2026-07-09T17:12:28+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.